Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration

Publication date: February 2019Source: The Lancet HIV, Volume 6, Issue 2Author(s): Intira J Collins, Kara Wools-Kaloustian, Ruth Goodall, Colette Smith, Elaine J Abrams, Jihane Ben-Farhat, Suna Balkan, Mary-Ann Davies, Andrew Edmonds, Valériane Leroy, Harriet Nuwagaba-Biribonwoha, Kunjal Patel, Mary E Paul, Jorge Pinto, Pablo Rojo Conejo, Annette Sohn, Russell Van Dyke, Rachel Vreeman, Nicky Maxwell, Venessa TimmermanSummaryBackgroundEstimates of incidence of switching to second-line antiretroviral therapy (ART) among children with HIV are necessary to inform the need for paediatric second-line formulations. We aimed to quantify the cumulative incidence of switching to second-line ART among children in an international cohort collaboration.MethodsIn this international cohort collaboration study, we pooled individual patient-level data for children younger than 18 years who initiated ART (two or more nucleoside reverse-transcriptase inhibitors [NRTI] plus a non-NRTI [NNRTI] or boosted protease inhibitor) between 1993 and 2015 from 12 observational cohort networks in the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. Patients who were reported to be horizontally infected with HIV and those who were enrolled in trials of treatment monitoring, switching, or interruption strategies were excluded. Switch to second-line ART was defined as change of one or more NRTI plus either change in drug class (NNRTI to protease inhibito...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research